Dicerna Pharmaceuticals (NASDAQ:DRNA) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03), Bloomberg Earnings reports. The business had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $10.95 million. Dicerna Pharmaceuticals had a negative return on equity of 48.98% and a negative net margin of 737.93%.
NASDAQ:DRNA traded down $0.19 during trading hours on Friday, reaching $13.59. 461,854 shares of the stock were exchanged, compared to its average volume of 370,559. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a 50-day simple moving average of $14.64. Dicerna Pharmaceuticals has a twelve month low of $9.31 and a twelve month high of $17.98. The stock has a market cap of $941.50 million, a P/E ratio of -11.33 and a beta of 2.16.
In other news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $12.50, for a total value of $20,000,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 21.28% of the stock is owned by corporate insiders.
Several research analysts recently weighed in on DRNA shares. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, July 2nd. SunTrust Banks decreased their price target on Dicerna Pharmaceuticals to $20.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. BidaskClub cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 6th. Finally, ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $21.57.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.